Inspired by those facts, we designed novel poly(butylene adipate-co-dilinoleic adipate) (PBA-DLA) block copolymer using enzyme lipase B from Candida antarctica (CALB) as biocatalyst to obtain fully biobased material since both monomers and catalyst are derived from natural sources. Enzymatic catalyst due to its high stereo-, enantio-, and regioselectivity can provide materials with a highly ordered structure which is a desirable feature, especially in the pharmaceutical industry. Immobilized form of CALB facilitates its easy removal after the synthesis and therefore no catalyst residues are remaining in the material matrix, which is very common drawback regarding metal-based catalysts . Furthermore, the results of the α-TPloaded nanocomposites using PBA-DLA as a carrier have been accomplished and the decisive role of a drug concentration on the NPs size and encapsulation efficiency has been investigated.